Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antiobesity evaluation of histamine H3 receptor (H3R) antagonist analogs of A-331440 with improved safety and efficacy.
Hancock AA, Diehl MS, Fey TA, Bush EN, Faghih R, Miller TR, Krueger KM, Pratt JK, Cowart MD, Dickinson RW, Shapiro R, Knourek-Segel VE, Droz BA, McDowell CA, Krishna G, Brune ME, Esbenshade TA, Jacobson PB. Hancock AA, et al. Among authors: cowart md. Inflamm Res. 2005 Apr;54 Suppl 1:S27-9. doi: 10.1007/s00011-004-0412-z. Inflamm Res. 2005. PMID: 15928821 No abstract available.
Selective H3 receptor (H3R) blockade: broad efficacy in cognition and schizophrenia.
Fox GB, Esbenshade TA, Pan JB, Browman KE, Zhang M, Ballard ME, Radek RJ, Miner H, Bitner RS, Krueger KM, Yao BB, Faghih R, Rueter LE, Komater VA, Drescher KU, Buckley MJ, Sullivan JP, Cowart MD, Decker MW, Hancock AA. Fox GB, et al. Among authors: cowart md. Inflamm Res. 2005 Apr;54 Suppl 1:S23-4. doi: 10.1007/s00011-004-0410-1. Inflamm Res. 2005. PMID: 15928819 No abstract available.
Distinctions and contradistinctions between antiobesity histamine H(3) receptor (H (3)R) antagonists compared to cognition-enhancing H (3) receptor antagonists.
Hancock AA, Bitner RS, Krueger KM, Otte S, Nikkel AL, Fey TA, Bush EN, Dickinson RW, Shapiro R, Knourek-Segel V, Droz BA, Brune ME, Jacobson PB, Cowart MD, Esbenshade TA. Hancock AA, et al. Among authors: cowart md. Inflamm Res. 2006 Apr;55 Suppl 1:S42-4. doi: 10.1007/s00011-005-0034-0. Inflamm Res. 2006. PMID: 16547814 No abstract available.
Minimization of potential hERG liability in histamine H3 receptor antagonists.
Black LA, Liu H, Diaz GJ, Fox GB, Browman KE, Wetter J, Marsh KC, Miller TR, Esbenshade TA, Brioni J, Cowart MD. Black LA, et al. Among authors: cowart md. Inflamm Res. 2008;57 Suppl 1:S45-6. doi: 10.1007/s00011-007-0622-2. Inflamm Res. 2008. PMID: 18345496 No abstract available.
In vitro optimization of structure activity relationships of analogues of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonists.
Hancock AA, Diehl MS, Faghih R, Bush EN, Krueger KM, Krishna G, Miller TR, Wilcox DM, Nguyen P, Pratt JK, Cowart MD, Esbenshade TA, Jacobson PB. Hancock AA, et al. Among authors: cowart md. Basic Clin Pharmacol Toxicol. 2004 Sep;95(3):144-52. doi: 10.1111/j.1742-7843.2004.950307.x. Basic Clin Pharmacol Toxicol. 2004. PMID: 15447739 Free article.
The medicinal chemistry of novel H(3) antagonists.
Cowart M, Faghih R, Gfesser G, Curtis M, Pratt JK, Bennani Y, Fox GB, Esbenshade TA, Hancock AA. Cowart M, et al. Inflamm Res. 2004 Mar;53 Suppl 1:S69-70. doi: 10.1007/s00011-003-0333-2. Epub 2004 Mar 5. Inflamm Res. 2004. PMID: 15054624 No abstract available.
78 results